IC
ACAD icon

IEQ Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

IEQ Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$415K Sell
16,394
-10,395
-39% -$229K ﹤0.01% 1486
2026
Q1 		$596K Sell
26,789
-55,555
-67% -$1.33M ﹤0.01% 1230
2025
Q4 		$2.2M Buy
82,344
+8,865
+12% +$212K 0.01% 759
2025
Q3 		$1.57M Buy
73,479
+26,061
+55% +$616K ﹤0.01% 845
2025
Q2 		$1.02M Buy
+47,418
New +$881K 0.01% 851

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

IEQ Capital's ACAD Position: Q2 2026 in Review

IEQ Capital reduced its Acadia Pharmaceuticals (ACAD) stake by 39% in Q2 2026, selling an estimated $229K and leaving 16,394 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #1486.

IEQ Capital first reported a position in ACAD in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.2M in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • IEQ Capital held 16,394 shares of Acadia Pharmaceuticals worth $415K as of Q2 2026.
  • IEQ Capital sold 10,395 Acadia Pharmaceuticals shares in Q2 2026, an estimated $229K.
  • Acadia Pharmaceuticals made up ﹤0.01% of IEQ Capital's portfolio in Q2 2026, its #1486 holding.
  • IEQ Capital first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • IEQ Capital's Acadia Pharmaceuticals position peaked at $2.2M in Q4 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on IEQ Capital's 13F filing for Q2 2026, filed 11 Aug 2026.